ISHL12 2022 | New findings and challenges in the use of immunotherapy in Hodgkin lymphoma
In this video, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses recent updates on the use of immunotherapy in Hodgkin lymphoma (HL), highlighting the promising results of PD1 inhibitors, novel antibody therapies, and CAR-T cell therapy. Prof. Ansell also comments on some challenges with the use of immunotherapy in HL, including the need to better understand pathways involved in this disease and investigate whether the innate immune system can be engaged in this space. This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding from Seattle Genetics, BMS, Affimed, Regeneron, Takeda, AstraZeneca, Pfizer, ADC Therapeutics to my institution for clinical trials.
